Dosing of Rosuvastatin for Patients with History of Myocardial Infarction

Recommended Dosing Strategy

• The American College of Cardiology recommends high-intensity statin therapy for all patients with a history of MI as part of secondary prevention, with rosuvastatin 20-40 mg daily considered high-intensity statin therapy, providing approximately 45-60% reduction in LDL-C 1, 2, 4
• The American Heart Association defines goal statin dosing for post-MI patients as achieving >75% of maximal statin potency, which for rosuvastatin is 20-40 mg daily 1, 2

Target LDL-C Goals

• The American College of Cardiology recommends a target LDL-C of less than 70 mg/dL for patients with a history of MI 6
• An even lower LDL-C target of less than 55 mg/dL may be considered for very high-risk patients 6

Monitoring and Follow-up

• The American Heart Association recommends obtaining baseline lipid profile, liver function tests, and creatine kinase before initiating therapy 4
• Follow-up lipid profile should be checked 4-12 weeks after initiating therapy to assess response 6

Clinical Evidence Supporting High-Intensity Statin Therapy

• High-intensity statin therapy after MI has been shown to reduce mortality, recurrent MI, and need for revascularization compared to moderate-intensity therapy 2, 6
• The American College of Cardiology guidelines support the use of high-intensity statin therapy to reduce major cardiovascular events in post-ACS patients 2, 6

Common Pitfalls to Avoid

• Underdosing statins is common, with approximately 73% of post-MI patients receiving suboptimal statin intensity 1, 2
• Failure to initiate statin therapy before hospital discharge significantly reduces long-term adherence 6
• Focusing solely on LDL-C levels rather than using the appropriate intensity of statin therapy based on risk category is a common pitfall 2, 3